Answers are grounded in this paper and cite their sources.
Knowledge regarding genomic aberrations resulting in progression of low-grade well-differentiated liposarcoma (WDLS) to high-grade dedifferentiated liposarcoma (DDLS) is limited. We analyzed DNA sequence, copy number, and gene expression in 9 paired WD/DDLS or WD/WDLS serial surgical samples to identify potential drivers of progression. We validated the relevance of events using samples collected from 265 patients and in vitro studies. All WDLS exhibited characteristic amplification of 12q13-15; additional, novel 6q23-25 gains were observed in 18% of WDLS and associated with higher local recurrence risk (HR=11, p<0.001). The 6q23-25 amplicon encoded TAB2, which was 2.1-fold overexpressed in WDLS samples with the event; in vitro TAB2 was necessary to prevent senescence and allow for MDM2 accumulation in 6q23-25-amplified WDLS cells but not in non-amplified WDLS or amplified DDLS cells. WDLS progression to DDLS was not associated with 6q23-25 amplification but with pathogenic ATRX mutations (7.6% vs 0%), 13q losses (22% vs 3.4%), and 8q12-21 gains (21% vs 5%). Downregulation of 13q genes MYCBP2 and IRS2 was observed in DDLS; in vitro, these genes were essential for WDLS cell differentiation. This study defines a longitudinal model of liposarcomagenesis with initiation characterized by 12q13-15 amplification, early WDLS progression through inhibition of senescence by 6q23-25 amplification, and progression to DDLS driven by ATRX mutations and/or tertiary copy number events (e.g., 13q loss, 8q12-21 gain). Implications: This study defines the role of recurrent copy number alterations and gene mutations in WD/DDLS initiation and progression, creating a detailed map of molecular events regulating liposarcomagenesis, patient outcome, and dedifferentiation.
No takes yet. Share an insight, caveat, or question.
Crago et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: